ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNDZ Sunridge International Inc (CE)

0.0001
0.00 (0.00%)
07 Feb 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunridge International Inc (CE) USOTC:SNDZ OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0001 0.00 00:00:00

Sunridge International Appoints CFO

09/03/2011 2:00pm

PR Newswire (US)


Sunridge (CE) (USOTC:SNDZ)
Historical Stock Chart


From Feb 2020 to Feb 2025

Click Here for more Sunridge (CE) Charts.

FOUNTAIN HILLS, Ariz., March 9, 2011 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today that it has appointed Charles B. Mathew CPA MBA as its CFO.

Sunridge CEO, G. Richard Smith stated, "We are moving fast with our business plan.  Recently the company made the decision to move into company owned and operated glaucoma treatment centers, to take advantage of the tremendous amount of money to be made treating patients with our patented PNT treatment for glaucoma and ocular hypertension.  While we are still expanding our distribution network around the world, the added revenue brought in by our clinical operations should accelerate the time needed to bring Sunridge to profitability.

We are moving forward to complete funding for our first clinic.  Mr. Mathew, will be a valuable asset throughout the fundraising process and in structuring our clinics.  For additional information on Mr. Mathew, please refer to our 8-K announcement."

Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide.  PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension.  The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International www.oi-pnt.com.



CONTACT:



Jeff Smith, Sunridge International



T:  +1-480-837-6165



e-mail: info@sunridgeint.com







MEDIA:



Victor Webb, Marston Webb International



T: (212) 684-6601



e-mail: marwebint@cs.com





SOURCE Sunridge International

Copyright 2011 PR Newswire

1 Year Sunridge (CE) Chart

1 Year Sunridge (CE) Chart

1 Month Sunridge (CE) Chart

1 Month Sunridge (CE) Chart

Your Recent History

Delayed Upgrade Clock